EnteroBiotix Commences the P-II Clinical Evaluation of EBX-102-02 for the Treatment of Irritable Bowel Syndrome (IBS)
Shots:
- EnteroBiotix has dosed the first patient with EBX-102-02 in the multi-centre, randomized P-II clinical evaluation for the treatment of irritable bowel syndrome (IBS)
- The P-II (TrIuMPH) study will evaluate the safety, efficacy & tolerability of EBX-102-02 in patients (n=60) with IBS and constipation in sites across in the UK for over 6wks. duration
- EBX-102-02, based on the company’s AMPLA technology, comprises of diverse microbial ecosystems and functional groups to restore and strengthen the microbiome
Ref: EnteroBiotix | Image: EnteroBiotix
Related News:- Bausch Health Launches Trulance (plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
